A combination product for hypertention was recently approved by the FDA. Tribenzor, the three-in-one product, uses other hypertention drugs olmesartan medoxomil, hydrochlorothiazide, and amlodipine to relax blood vessels and allows blood to flow more freely. This combination product hopes to help those with hypertension by simplifying pill regiments, reduce the number of pills a patient takes and lower co-pay for the pills. It is hoped that this combination product will allow more individuals to reach their goal for their best blood pressure.
Modern Medicine has more on the new combination product.
|
Share this article with your social network, just click below to share now!
|
|
|
The global synthetic biology market is supposed to reach $13.4 billion by 2019. A recent study from Transparency Market Research shows that...
Oren Levy from Karp Lab gave an excellent talk called “MSCs on Steriods” last month at Biotech Week Boston. Oren's research focus is &q...
If you blink you will most likely miss some major design, invention or discovery in the robotics industry. The future is definitely here, an...
No comments :
Post a Comment